G1SK34:BVMF
Gsk Plc Bdr
50,50 BRL
0,00%
(0,00) 1D
16 tet, 4:56:00 m.d., GMT-3 · BRL
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për G1SK34...
Hap
50,10 BRL
I lartë
50,75 BRL
I ulët
50,10 BRL
Kapitalizimi i tregut
100,21 mld
Vëllimi mesatar
214,00
Vëllimi
165,00
Maksimumi 52-javor
63,24 BRL
Minimumi 52-javor
46,15 BRL
Aksionet në qarkullim
4,32 mld
Numri i punonjësve
67 mijë
Hap
50,10 BRL
I lartë
50,75 BRL
I ulët
50,10 BRL
Kapitalizimi i tregut
100,21 mld
Vëllimi mesatar
214,00
Vëllimi
165,00
Maksimumi 52-javor
63,24 BRL
Minimumi 52-javor
46,15 BRL
Aksionet në qarkullim
4,32 mld
Numri i punonjësve
67 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
The Globe and Mail
·
13 orë më parë
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Traders Union
·
17 orë më parë
GSK shares technical analysis: Overbought conditions highlight reversal setup
JournalArta
·
23 orë më parë
GSK Stock Gains 2.89% on Thursday: Full Details
Yahoo Finance
·
1 ditë më parë
Better Dividend Stock: Pfizer vs. GSK
Profili
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Rreth Gsk Plc Bdr
Drejtori ekzekutivEmma Walmsley | Emma Walmsley
Punonjësit66,8 mijë
Themeluar më27 dhj 2000
Selia-
Sektori-
Uebsajtigsk.com